ARTICLE | Clinical News
Novuspharma Phase II NHL results
December 10, 2001 8:00 AM UTC
Novuspharma (NMerc:NOV) said in an open-label European Phase II trial of its BBR 2778 aza-anthracenedione DNA intercalating agent, 9 of 33 patients with non-Hodgkin's lymphoma (NHL) responded and 5 ha...